SRZN Surrozen, Inc./DE
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%
Returns
ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.48M | $10.65M | $0 | $12.50M | $0 |
| R&D expense | $29.36M | $21.13M | $27.23M | $37.01M | $40.18M |
| SG&A expense | $16.20M | $15.06M | $15.80M | $19.83M | $14.21M |
| Operating income | -$42.09M | -$25.54M | -$45.78M | -$44.34M | -$54.39M |
| Pretax income | -$242.03M | -$63.56M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$242.03M | -$63.56M | -$43.04M | -$36.00M | -$54.65M |
| EBITDA | -$41.55M | -$24.10M | -$43.87M | -$42.38M | -$52.33M |
| EPS (basic) | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 |
| EPS (diluted) | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 |
| Weighted avg. shares (diluted) | 7,478 | 2,933 | 2,018 | 2,314 | 24,689 |
| Balance sheet | |||||
| Cash & equivalents | $89.25M | $35.25M | $36.73M | $25.09M | $33.50M |
| Short-term investments | — | — | $0 | $51.15M | $68.76M |
| Receivables | $0 | $2.04M | $2.15M | $1.98M | $0 |
| Current assets | $91.56M | $38.93M | $41.13M | $81.31M | $105.19M |
| PP&E, net | $433,000 | $562,000 | $1.97M | $3.63M | $4.79M |
| Total assets | $98.73M | $48.47M | $46.08M | $89.44M | $137.17M |
| Current liabilities | $9.93M | $7.32M | $7.15M | $9.73M | $13.57M |
| Total liabilities | $286.49M | $69.85M | $8.14M | $13.43M | $27.47M |
| Shareholders' equity | -$187.76M | -$21.38M | $37.94M | $76.00M | $109.70M |
| Shares outstanding | 9.78M | 3.26M | 2.06M | 2.01M | 35.03M |
| Cash flow statement | |||||
| Operating cash flow | -$30.24M | -$17.63M | -$40.36M | -$44.15M | -$48.81M |
| Capital expenditure | $128,000 | $26,000 | $398,000 | $728,000 | $1.27M |
| Free cash flow | -$30.37M | -$17.65M | -$40.76M | -$44.87M | -$50.08M |
| Investing cash flow | -$128,000 | -$26,000 | $51.72M | $38.31M | -$77.71M |
| Financing cash flow | $85.05M | $16.18M | $276,000 | -$2.56M | $124.63M |
| Depreciation & amortization | $537,000 | $1.44M | $1.91M | $1.96M | $2.07M |
| Stock-based compensation | $3.83M | $4.11M | $4.37M | $4.52M | $2.32M |
| Share buybacks | — | — | $0 | $2.61M | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.